Franklin Genomic Advancements ETF HELX

Medalist Rating as of | See Franklin Templeton Investment Hub

Morningstar’s Analysis HELX

Will HELX outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

Franklin Genomic Advancements ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings HELX

  • Current Portfolio Date
  • Equity Holdings —
  • Bond Holdings —
  • Other Holdings —
  • % Assets in Top 10 Holdings 49.0
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Natera Inc

10.45 4M
Healthcare

Guardant Health Inc

9.29 3M
Healthcare

Krystal Biotech Inc

5.04 2M
Healthcare

Ligand Pharmaceuticals Inc

4.61 2M
Healthcare

Adaptive Biotechnologies Corp

4.33 2M
Healthcare

Twist Bioscience Corp

4.16 1M
Healthcare

BridgeBio Pharma Inc

2.93 1M
Healthcare

Medpace Holdings Inc

2.88 999,682
Healthcare

Vertex Pharmaceuticals Inc

2.67 925,778
Healthcare

United Therapeutics Corp

2.65 920,743
Healthcare

Sponsor Center